Precision for Value Buys Health Economics Firm – Medical Marketing & Media
Precision’s acquisition of Redwood Outcomes is noted in Medical Marketing & Media.
Precision for Value Acquires Redwood Outcomes
Extends Leadership and Global Reach in Health Economics and Outcomes Research
Gladstone, N.J. and Vancouver, B.C., November 4, 2015 – Precision for Value (Precision) today announced that it has acquired Redwood Outcomes, a leading international health economics and outcomes research (HEOR) company. Redwood Outcomes serves pharmaceutical and biotechnology companies and applies the science of evidence generation, synthesis, and modeling to optimize healthcare decision making.
Commentary: How to Evaluate the Opportunity of Indication-Based Drug Contracting
Precision for Value’s Jeremy Schafer discusses the concept of indication-based drug contracting and how it could represent a new frontier of manufacturer-payer agreements.
Commentary: Understanding Health Care’s Short-Termism Problem
Precision’s Chief Scientific Officer Amitabh Chandra and PHE founding partner Dana Goldman address health care’s Short-Termism problem in their latest article for the Harvard Business Review.
Sandoz’ Filgrastim Biosimilar Is Now on the US Market – Pharmaceutical Commerce Magazine
Precision for Medicine’s Larry Blandford quoted in an article from Pharmaceutical Commerce magazine on a new biosimilar product from Novartis’ Sandoz unit called Zarxio.